SWOG S1505: results of chemotherapy (mFOLFIRINOX) versus perioperative Gemcitabine / nab-Paclitaxel for resectable pancreatic ductal adenocarcinoma (PDA)

The authors concluded that there is little evidence that either regimen improves overall survival compared to the historical pattern of treatment.

SWOG S1505 is a prospective, randomized, phase II trial presented at the ASCO 2020 Virtual Annual Meeting, which sought to assess the potential of multiagent perioperative chemotherapy (CTpo) (12 weeks before and 12 weeks after surgery with mFOLFIRINOX versus gemcitabine + nab Paclitaxel [Gem / nabP]) in the early control of systemic disease in patients with resectable pancreatic ductal adenocarcinoma (rPDA).

From 2015 to 2018, 147 patients were recruited. The eligibility criteria involved pathological confirmation of ADP, ECOG 0 or 1 and resectable disease. The primary endpoint was overall survival (SG) at 2 years. 102 were eligible: 55 individuals in arm 1 (mFOLFIRINOX) and 47 in arm 2 (Gem / nabP). For arms 1 and 2, respectively: median age, 66 (44-76) and 64 (46-76) years; men, 36 (65%) and 24 (51%); and ECOG 0, 34 (62%) and 31 (66%) patients.

For arm 1 and arm 2, respectively: OS in two years was 41.6% and 48.8%; Median OS was 22.4 months and 23.6 months. No estimate of OS for both arms in 2 years was greater than the initial threshold of 40% (p = 0.42 in arm 1; p = 0.12 in arm 2). The median disease-free survival (DFS) after resection was 10.9 months in arm 1 and 14.2 months in arm 2 (p = 0.87).

The authors concluded that there is little evidence that either regimen improves OS compared to the historical pattern of treatment.

Learn more:
J Clin Oncol 38: 2020 (suppl; abstr 4504). DOI:10.1200/JCO.2020.38.15_suppl.4504
https://meetinglibrary.asco.org/record/185465/abstract